OR WAIT null SECS
The partnership between Clinerion and OncologyInformationService (O.I.s) will create a platform for oncology which integrates O.I.s’s real-world databases with Clinerion’s patient data network, via Clinerion’s patented patient data analytics technologies. The partners aim to establish a real-world evidence (RWE) database from a network of cancer treating institutions which will also allow real-time query of the participating institutions’ electronic medical records (EMRs). This platform will leverage the aggregated data to deliver:
O.I.s provides a deep knowledge of treatment algorithms in oncology and hematology and approved methodologies for collection and analyses of treatment algorithms based on longitudinal real-world data from patient files in treating institutions. O.I.s will provide the Clinerion partnership with access to its established RWE cooperative group consisting of patient organizations and a network of oncologists/hematologists, its real-world databases and its approved methodologies for collecting and analyzing RWE data.
Clinerion’s Patient Network Explorer (PNEx) allows query of anonymized patient data among its network of partner hospitals to generate real-world data based on EMR. In the partnership, Clinerion will provide PNEx technology as the platform to query both partners’ databases, taking advantage of its fast data collection and real-time update capability.
The partners’ new platform will also incorporate genomic technology and PRO/PRE reporting via an additional partnership with Andaman7.
“The partnership with Clinerion will allow O.I.s to provide unbiased and complete RWE faster than before and to involve cancer-treating institutions, globally. O.I.s will use the resulting enormous, combined database for high-end analyses, meeting the information needs from all stakeholders in the fight against cancer,” saysLenka Kellermann, founder and owner of O.I.s.
“This partnership represents a deepening of Clinerion’s commitment to providing our real-world data solutions in the oncology space, which represents 40% of all drug development pipeline expenditure,” says Ian Rentsch, CEO of Clinerion. “Clinerion’s services are otherwise agnostic to treatment area, being based on hospital EMR data.”